相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Correlates of protection against SARS-CoV-2 in rhesus macaques
Katherine McMahan et al.
NATURE (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
An interactive web-based dashboard to track COVID-19 in real time
Ensheng Dong et al.
LANCET INFECTIOUS DISEASES (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
Paul-Henri Lambert et al.
VACCINE (2020)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan et al.
NATURE (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence
Catherine Cohet et al.
VACCINE (2019)
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Jesper Pallesen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial
Geert Leroux-Roels et al.
CLINICAL IMMUNOLOGY (2016)
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination
Javier Diez-Domingo et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2015)
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response A Randomized Clinical Trial
Lisa A. Jackson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
Fernanda Tavares Da Silva et al.
VACCINE (2013)
Recombinant vaccines and the development of new vaccine strategies
I. P. Nascimento et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2012)
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2012)
AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method
Marie-Francoise Klucker et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
Chien-Te Tseng et al.
PLoS One (2012)
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 mo to 17 y of age
Timo Vesikari et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Philippe Moris et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV
Fumihiko Yasui et al.
JOURNAL OF IMMUNOLOGY (2008)
An adjuvanted, low-dose, pandemic influenza a (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
Karin Levie et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
M Czub et al.
VACCINE (2005)
分享论文
